Following a thorough evaluation of the available data, the National Institute for Health and Care Excellence (NICE) has decided to make a groundbreaking cancer therapy available through the NHS. This comes nearly a year after initial recommendations from the organization advised against its regular use due to a lack of sufficient evidence.

The combination of amivantamab and lazertinib is set to be introduced on the NHS as a treatment option for individuals diagnosed with a particular form of advanced lung cancer. NICE has indicated that this treatment could potentially aid hundreds of people across the UK. On January 21, NICE released new guidance, stating, “More than 1,100 patients with a type of advanced lung cancer will now have access to a new first-line treatment.”

The conclusive guidance from NICE endorses the use of amivantamab with lazertinib for patients with untreated EGFR mutation-positive advanced non-small-cell lung cancer.

NICE has assured patients that this introduction means healthcare providers should offer comprehensive information, engage in discussions about available options, and be attentive to their opinions and concerns. Patients are encouraged to involve their families in these discussions if desired.

Lazertinib is generally taken as a daily oral pill, while amivantamab is typically delivered through an intravenous (IV) infusion. The Medicines and Healthcare products Regulatory Agency had previously approved this combination treatment for patients last March.

This treatment has already been available through the NHS in Scotland and will now extend its availability to patients in England as well.

In July 2025, NICE initiated a consultation to determine if the drug should be utilised in the NHS. In its draft guidance, it stated: “Amivantamab plus lazertinib is not required to be funded in the NHS in England… It should not be used routinely in the NHSin England.

“This is because there is not enough evidence to determine whether amivantamabplus lazertinib is value for money in this population.”

During the consultation, NICE discovered clinical trial evidence indicating that the combination of amivantamab plus lazertinib prolongs the period before a patient’s condition worsens. It could also extend life expectancy compared with other standalone treatment options currently available.

Now, following this consultation, it has issued the final guidance which found: “Amivantamab plus lazertinib must be funded in the NHS in England for the condition and population in the recommendations, if it is considered the most suitable treatment option.

“Amivantamab plus lazertinib must be funded in England within 90 days of final publication of this guidance.

“There is enough evidence to show that amivantamab plus lazertinib provides benefits and value for money, so it can be used routinely across the NHS in this population.”